Inflammation-induced activation of the indoleamine 2,3-dioxygenase pathway: Relevance to cancer-related fatigue

Cancer

Volumn 121, Issue 13, 2015, Pages 2129-2136

  Kim, Sangmi ^a   Miller, Brian J ^a   Stefanek, Michael E ^b   Miller, Andrew H ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

fatigue; indoleamine 2,3 dioxygenase; inflammation; kynurenine (KYN); neoplasms; neurobehavioral manifestations; risk factors

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; SEROTONIN;

ANXIETY; BIOACCUMULATION; BIOLOGICAL MONITORING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELATED FATIGUE; CATABOLISM; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVATION; ENZYME ACTIVITY; FATIGUE; HUMAN; INFLAMMATION; INSOMNIA; MALIGNANT NEOPLASTIC DISEASE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEROTONIN RELEASE; ANIMAL; COMPLICATION; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ENZYME ACTIVATION; FATIGUE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; NEOPLASMS;

EID: 84931037860     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29302     Document Type: Review

References (71)

1. Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M,. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res. 2010; 19: 1419-1427.
2. Berger AM, Abernethy AP, Atkinson A, et al., Cancer-related fatigue. J Natl Compr Canc Netw. 2010; 8: 904-931.
3. Pachman DR, Barton DL, Swetz KM, Loprinzi CL,. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012; 30: 3687-3696.
4. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR,. Mechanisms of cancer-related fatigue. Oncologist. 2007; 12 (suppl 1): 22-34.
5. Bower JE, Lamkin DM,. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013; 30 (suppl): S48-S57.
6. Seruga B, Zhang H, Bernstein LJ, Tannock IF,. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008; 8: 887-899.
7. Bower JE, Ganz PA, Aziz N, Fahey JL,. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002; 64: 604-611.
8. Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW,. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011; 29: 3517-3522.
9. Dantzer R, O'Connor JC, Lawson MA, Kelley KW,. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011; 36: 426-436.
10. Miller AH, Maletic V, Raison CL,. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65: 732-741.
11. Capuron L, Pagnoni G, Drake DF, et al., Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry. 2012; 69: 1044-1053.
12. Capuron L, Miller AH,. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004; 56: 819-824.
13. Capuron L, Gumnick JF, Musselman DL, et al., Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002; 26: 643-652.
14. Morrow GR, Hickok JT, Roscoe JA, et al., Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21: 4635-4641.
15. Bardwell WA, Natarajan L, Dimsdale JE, et al., Objective cancer-related variables are not associated with depressive symptoms in women treated for early-stage breast cancer. J Clin Oncol. 2006; 24: 2420-2427.
16. Bower JE, Ganz PA, Desmond KA, et al., Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006; 106: 751-758.
17. Fagundes CP, Bennett JM, Alfano CM, et al., Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer. Health Psychol. 2012; 31: 11-19.
18. Alexander S, Minton O, Andrews P, Stone P,. A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer. 2009; 45: 384-392.
19. Landmark-Hoyvik H, Reinertsen KV, Loge JH, Fossa SD, Borresen-Dale AL, Dumeaux V,. Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J. 2009; 9: 333-340.
20. Smith AK, Conneely KN, Pace TW, et al., Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun. 2014; 38: 227-236.
21. Reinertsen KV, Cvancarova M, Loge JH, Edvardsen H, Wist E, Fossa SD,. Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv. 2010; 4: 405-414.
22. Fagundes CP, Lindgren ME, Shapiro CL, Kiecolt-Glaser JK,. Child maltreatment and breast cancer survivors: social support makes a difference for quality of life, fatigue and cancer stress. Eur J Cancer. 2012; 48: 728-736.
23. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R,. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A. 2007; 104: 1319-1324.
24. Miller GE, Cole SW,. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry. 2012; 72: 34-40.
25. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH,. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord. 2009; 119: 181-185.
26. Munn DH, Mellor AL,. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013; 34: 137-143.
27. Ardis TC, Cahir M, Elliott JJ, Bell R, Reynolds GP, Cooper SJ,. Effect of acute tryptophan depletion on noradrenaline and dopamine in the rat brain. J Psychopharmacol. 2009; 23: 51-55.
28. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D,. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006; 364: 82-90.
29. Guillemin GJ, Smythe G, Takikawa O, Brew BJ,. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005; 49: 15-23.
30. Kim H, Chen L, Lim G, et al., Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest. 2012; 122: 2940-2954.
31. Munn DH,. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006; 18: 220-225.
32. McGaha TL, Huang L, Lemos H, et al., Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev. 2012; 249: 135-157.
33. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R,. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011; 17: 6985-6991.
34. Uyttenhove C, Pilotte L, Theate I, et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003; 9: 1269-1274.
35. Laich A, Neurauter G, Widner B, Fuchs D,. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem. 2002; 48: 579-581.
36. Kurz K, Fiegl M, Holzner B, et al., Fatigue in patients with lung cancer is related with accelerated tryptophan breakdown. PLoS One. 2012; 7: e36956.
37. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG,. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer. 2002; 86: 1691-1696.
38. Schroecksnadel K, Fiegl M, Prassl K, Winkler C, Denz HA, Fuchs D,. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol. 2007; 133: 477-485.
39. van Donkelaar EL, Blokland A, Ferrington L, Kelly PA, Steinbusch HW, Prickaerts J,. Mechanism of acute tryptophan depletion: is it only serotonin? Mol Psychiatry. 2011; 16: 695-713.
40. Carpenter LL, Anderson GM, Pelton GH, et al., Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology. 1998; 19: 26-35.
41. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R,. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002; 7: 468-473.
42. Raison CL, Dantzer R, Kelley KW, et al., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010; 15: 393-403.
43. Neumeister A, Konstantinidis A, Stastny J, et al., Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch Gen Psychiatry. 2002; 59: 613-620.
44. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ,. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13: 465-477.
45. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW,. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9: 46-56.
46. Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MA, Colton CA,. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport. 1997; 8: 431-434.
47. Chen Y, Guillemin GJ,. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009; 2: 1-19.
48. Haroon E, Woolwine BJ, Chen X, et al., IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology. 2014; 39: 1777-1785.
49. Walker AK, Budac DP, Bisulco S, et al., NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013; 38: 1609-1616.
50. Abbott NJ,. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000; 20: 131-147.
51. Midttun O, Kvalheim G, Ueland PM,. High-throughput, low-volume, multianalyte quantification of plasma metabolites related to one-carbon metabolism using HPLC-MS/MS. Anal Bioanal Chem. 2013; 405: 2009-2017.
52. Hustad S, Eussen S, Midttun O, et al., Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem. 2012; 58: 402-410.
53. Midttun O, Townsend MK, Nygard O, et al., Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. J Nutr. 2014; 144: 784-790.
54. Pertovaara M, Raitala A, Juonala M, et al., Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007; 148: 106-111.
55. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D,. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem. 2004; 37: 684-687.
56. Theofylaktopoulou D, Midttun O, Ulvik A, et al., A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013; 173: 121-130.
57. Pertovaara M, Raitala A, Lehtimaki T, et al., Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev. 2006; 127: 497-499.
58. 2-microglobulin changes. Neurosignals. 2005; 14: 126-135.
59. Andrykowski MA, Donovan KA, Laronga C, Jacobsen PB,. Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer. 2010; 116: 5740-5748.
60. Schmitz KH, Neuhouser ML, Agurs-Collins T, et al., Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013; 105: 1344-1354.
61. Mautino MR, Jaipuri FA, Waldo J, et al., NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res. 2013; 73: 491.
62. Muller AJ, Malachowski WP, Prendergast GC,. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets. 2005; 9: 831-849.
63. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC,. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11: 312-319.
64. Hou DY, Muller AJ, Sharma MD, et al., Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007; 67: 792-801.
65. Prendergast GC, Smith C, Thomas S, et al., Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014; 63: 721-735.
66. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC,. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007; 67: 7082-7087.
67. O'Connor JC, Lawson MA, Andre C, et al., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009; 14: 511-522.
68. O'Connor JC, Lawson MA, Andre C, et al., Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol. 2009; 182: 3202-3212.
69. Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Fuchs D,. Aspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitro. Clin Exp Immunol. 2005; 140: 41-45.
70. Ye XF, Wang J, Shi WT, He J,. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer. 2014; 111: 2172-2179.
71. Chaouloff F,. Effects of acute physical exercise on central serotonergic systems. Med Sci Sports Exerc. 1997; 29: 58-62.